CNRS UMR 5164, ImmunoConcEpT, Biological and Medical Sciences Department, University of Bordeaux, 33076 Bordeaux, France.
Cancer Biology Graduate Program, UB Grad 2.0, University of Bordeaux, 33076 Bordeaux, France.
Int J Mol Sci. 2023 Oct 10;24(20):15048. doi: 10.3390/ijms242015048.
Breast cancers regroup many heterogeneous diseases unevenly responding to currently available therapies. Approximately 70-80% of breast cancers express hormone (estrogen or progesterone) receptors. Patients with these hormone-dependent breast malignancies benefit from therapies targeting endocrine pathways. Nevertheless, metastatic disease remains a major challenge despite available treatments, and relapses frequently ensue. By improving patient survival and quality of life, cancer immunotherapies have sparked considerable enthusiasm and hope in the last decade but have led to only limited success in breast cancers. In addition, only patients with hormone-independent breast cancers seem to benefit from these immune-based approaches. The present review examines and discusses the current literature related to the role of hormone receptor signaling (specifically, an estrogen receptor) and the impact of its modulation on the sensitivity of breast cancer cells to the effector mechanisms of anti-tumor immune responses and on the capability of breast cancers to escape from protective anti-cancer immunity. Future research prospects related to the possibility of promoting the efficacy of immune-based interventions using hormone therapy agents are considered.
乳腺癌是一组异质性很强的疾病，对目前可用的治疗方法反应不一。大约 70-80%的乳腺癌表达激素（雌激素或孕激素）受体。这些依赖激素的乳腺癌恶性肿瘤患者受益于针对内分泌途径的治疗方法。然而，尽管有可用的治疗方法，转移性疾病仍然是一个主要挑战，并且经常复发。在过去十年中，癌症免疫疗法极大地激发了人们的热情和希望，提高了患者的生存率和生活质量，但在乳腺癌中仅取得了有限的成功。此外，似乎只有激素非依赖性乳腺癌患者受益于这些基于免疫的方法。本文综述了与激素受体信号（特别是雌激素受体）的作用及其对乳腺癌细胞对抗肿瘤免疫反应效应机制的敏感性以及乳腺癌逃避保护性抗癌免疫能力的影响相关的当前文献，并讨论了相关内容。还考虑了使用激素治疗剂来提高基于免疫的干预措施的疗效的未来研究前景。
